Oral Session

[O3] Oral Session 3"Cancer 1"

Mon. Sep 11, 2023 3:25 PM - 4:35 PM Room 3 (1008, 10Ｆ, OICC)

Chairs:Hideki Kasuya（Nagoya University, Cancer Immune therapy center）,Shuji Kubo（Laboratory of Molecular and Genetic Therapeutics, Institute for Advanced Medical Sciences, Hyogo Medical University）

+Add all to schedule

[O3-1] Anti-tumor immune responses of oncolytic vaccinia virus are synergistically enhanced by induction of cell-cell fusion and delivery of multiple immunomodulators

^○Motomu Nakatake, Emi Kaitsurumaru, Hajime Kurosaki, Takafumi Nakamura (Division of Genomic Medicine, Graduate School of Medical Sciences, Tottori University, Yonago, Japan)

[O3-2] Combination Therapy of HSV-1 based Oncolytic Virotherapy with STING activator 2'3'-cGAMP Synergistically Amplifies Systemic Anti-Tumor Immunity

^○Patricia Angela Alvero Sibal^1,2, Shigeru Matsumura¹, Toru Ichinose¹, Itzel Villalobos Bustos¹, Daishi Morimoto^1,2, Ibrahim Ragab Eissa^1,2,3, Mohamed Abdelmoneim^1,2,4, Mona Al Hussein Mostafa Aboalela^1,2,5, Nobuaki Mukoyama⁶, Maki Tanaka⁷, Yoshinori Naoe¹, Hideki Kasuya¹ (1.Cancer Immune Therapy Research Center, International Medical Education, Nagoya University, Graduate School of Medicine, 2.Department of Surgery II, Nagoya University, Graduate School of Medicine, 3.Sci., Tanta Univ., Egypt, 4.Microbiol., Vet. Med., Zagazig Univ., Egypt, 5.Med. Microbiol. and Immun., Zagazig Univ., Egypt, 6.Otol. Grad. Sch. Med., Nagoya Univ., 7.Takara Bio Inc.)

[O3-3] Oncolytic virus-infected-mesenchymal stem cells contribute to the enhanced antitumor immunity

^○Shigeru Matsumura¹, Patricia Angela Alvero Sibal^1,2, Itzel Villalobos Bustos¹, Mohamed Abdelmoneim^1,2,3, Mona Al Hussein Mostafa Aboalela^1,2,4, Nobuaki Mukoyama⁵, Yoshinori Naoe¹, Hideki Kasuya¹ (1.Cancer Immune Therapy Research Center, International Medical Education, Nagoya University, Graduate School of Medicine, 2.Department of Surgery II, Nagoya University, Graduate School of Medicine, 3.Microbiol., Vet. Med., Zagazig Univ., Egypt, 4.Med. Microbiol. and Immun., Zagazig Univ., Egypt, 5.Otol. Grad. Sch. Med., Nagoya Univ.)

[O3-4] Interferon-expressing oncolytic adenovirus　+ chemoradiation inhibited tumor growth in a hamster pancreatic cancer model

^○Shuhei Shinoda^1,2, Kazuho Inoko², Mizuho Sato-Dahlman², Masato Yamamoto² (1.Department of gastroenterology and hepatology, Yamaguchi Univerisity Graduate School of Medicine, 2.Department of Surgery, University of Minnesota)

[O3-5] Suicide gene therapy using retroviral replicating vectors for gastric cancer

^○Shuji Kubo¹, Hiroaki Fujino¹, Noriyuki Kasahara², Emiko Sonoda-Fukuda¹ (1.Laboratory of Molecular and Genetic Therapeutics, Institute for Advanced Medical Sciences, Hyogo Medical University, 2.Departments of Neurological Surgery and Radiation Oncology, University of California, San Francisco, USA)

[O3-6] Augmentation of anti-tumor effects of receptor-retargeted oncolytic HSV (RR-oHSV) through introduction of syn mutations

^○Takuma Suzuki¹, Hideaki Tahara², Hiroaki Uchida¹ (1.Tokyo University of Pharmacy and Life Sciences, 2.Osaka International Cancer Institute)

[O3-7] Therapeutic potential of oncolytic adenovirus against cancer-associated fibroblast phenotypes induced by pancreatic cancer cells

^○Yasuo Nagai¹, Hiroshi Tazawa^1,2, Hiroaki Inoue¹, Satoru Kikuchi¹, Shinji Kuroda¹, Yasuo Urata³, Shunsuke Kagawa¹, Toshiyoshi Fujiwara¹ (1.Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 2.Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan, 3.Oncolys BioPharma, Inc., Tokyo, Japan)